General Information |
| Summary |
This is an open-label, multicenter, Phase 1 study evaluating the safety and tolerability of VCTX210A combination product in patients with T1D |
| Description |
VCTX210A combination product (unit) comprises 2 components: (1) allogeneic pancreatic endoderm cells (PEC210A) genetically modified using Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9 (CRISPR/Cas9) to promote immune evasiveness and survival, and (2) a durable, removable, perforated device designed to deliver and retain the PEC210A cells. |
| Clinical trials phase |
Phase 1 |
| Start date (estimated) |
2022-01-24 |
| End date (estimated) |
2023-01-19 |
| Clinical feature |
| Label |
type 1 diabetes mellitus |
| Link |
http://purl.obolibrary.org/obo/DOID_9744 |
| Description |
A diabetes mellitus that is characterized by destruction of pancreatic beta cells resulting in absent or extremely low insulin production.; Xref MGI. OMIM mapping confirmed by DO. [SN]. |
|
Administrative Information |
| NCT number |
NCT05210530 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT05210530 |
| Other study identifiers |
|
| Source weblink |
https://clinicaltrials.gov/ct2/show/NCT05210530 |
| Sponsors |
CRISPR Therapeutics AG
|
| Collaborators |
|
Cells |
| Source pluripotent stem cell lines |
|
| Which differentiated cell type is used |
| Label |
progenitor cell of endocrine pancreas |
| Link |
http://purl.obolibrary.org/obo/CL_0002351 |
| Description |
A progenitor cell that is able to differentiate into the pancreas alpha, beta and delta endocrine cells. This cell type expresses neurogenin-3 and Isl-1. |
|
Recruitment |
| Recruitment Status |
Completed |
| Estimated number of participants |
7 |
